Premaitha Health PLC Collaboration with Abnova (6375S)
June 26 2018 - 8:31AM
UK Regulatory
TIDMNIPT
RNS Number : 6375S
Premaitha Health PLC
26 June 2018
Premaitha Health plc
("Premaitha" or the "Company")
Collaboration with Abnova
Partnership to develop next generation sequencing capability for
single cell analysis
Manchester, UK - 26 June 2018: Premaitha Health plc (AIM: NIPT),
a leading international molecular diagnostics group, announces that
it has entered into a partnership with Abnova, the world's largest
monoclonal antibody manufacturer, to collaborate on the development
of next generation sequencing ("NGS") capabilities for single cell
analysis.
Abnova has successfully developed a large portfolio of
cell-based liquid biopsy technologies, focused on the enrichment
and isolation of circulating tumour cells ("CTC") and circulating
fetal cells ("CFC"). Premaitha, through its Yourgene subsidiary,
will work with Abnova in Taiwan to build the single cell NGS
infrastructure for the analysis of CTCs and CFCs.
Premaitha and Abnova will work together in order to accelerate
the adoption of a laboratory-developed single cell test by
integrating their respective systems and developing the
applications for in vitro diagnostics, as well as commercialising
the test for the cancer and prenatal markets.
Dr Stephen Little, CEO of Premaitha, commented: "In
biotechnology, collaboration is essential and we are thrilled to be
partnering with a company of Abnova's calibre, who we believe have
the complementary expertise to our Yourgene team to drive the
development of NGS capabilities for single cell analysis. This
partnership further evidences the continued progress we are making
in extending our potential product range by leveraging our
underlying technologies and developing key collaboration
partnerships."
For more information, please contact:
Premaitha Health PLC Tel: +44 (0)161
Dr Stephen Little, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213
Liam Murray / James Caithie 0880
finnCap (Broker) Tel: +44 (0)20 7220
Adrian Hargrave / Scott Mathieson (Corporate 0500
Finance)
Andrew Burdis / Abigail Wayne (Corporate Broking)
Vigo Communications Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0237
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests.
The Group's current primary focus is on non-invasive prenatal
tests (NIPT) for pregnant women - an emerging, multi-billion dollar
global market - although the Group intends to expand its product
range into other areas of clinical genetics.
Premaitha's first product, the IONA(R) test was launched in 2015
as the first CE-IVD NIPT test in Europe. It enables laboratories
and healthcare practitioners to offer a complete CE-marked NIPT
system in-house. The IONA(R) test is performed on a maternal blood
sample - which contains traces of fetal DNA - and estimates the
risk of a fetus being affected with Down's syndrome or other
genetic conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening solution that operates
on the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
From May 2018, the Group will trade as Yourgene Health outside
of Europe (but remaining as Yourgene Bioscience in Taiwan)
reflecting the increased scope of the business in other areas of
clinical genetics further to reproductive health; but will maintain
the Premaitha Health brand within Europe.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLQLFLVQFLBBK
(END) Dow Jones Newswires
June 26, 2018 08:31 ET (12:31 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024